Key result
Combination chemotherapy with cis-platin, doxorubicin, and cyclophosphamide (CAP) achieved a 63% overall response rate in patients with metastatic breast cancer.
Why the study?
Does CAP chemotherapy (cis-platin, doxorubicin, and cyclophosphamide) induce tumor response in patients with metastatic breast cancer?
Does CAP chemotherapy (cis-platin, doxorubicin, and cyclophosphamide) induce tumor response in patients with metastatic breast cancer?
The CAP regimen demonstrates clinical activity in advanced breast carcinoma with an overall response rate of 63% and acceptable tolerance.
Answers are grounded in this paper and cite their sources.
CAP shows activity in metastatic breast cancer; leaves open comparative efficacy and survival benefit versus modern regimens.
Thirty-three evaluable patients with metastatic breast cancer (12 previously treated with adjuvant chemotherapy) were treated with a combination of cis-platin, doxorubicin, and cyclophosphamide (CAP). cis-Platin was given intravenously, 20 mg/m2, on days 1-3, doxorubicin, 40 mg/m2 i.v., on day 1, and cyclophosphamide, 200 mg/m2 i.v., on days 1-3. Cycles were repeated every 3 weeks. A complete response (CR) was obtained in 3 patients (9%) and a partial response (PR) in 18 (54%). The highest response rate was observed in soft tissue and in liver metastases. Median response duration was 48 weeks and median survival 93 weeks. Toxicity was moderate and consisted of alopecia (100%), gastrointestinal toxicity (86%), and myelosuppression (60%). We conclude that this regimen is active in the treatment of advanced breast carcinoma, with a generally acceptable tolerance, but further evaluations in Phase III studies are required.
No takes yet. Share an insight, caveat, or question.
Colozza et al. (1989) studied Metastatic breast cancer (n=33). cis-Platin, doxorubicin, and cyclophosphamide (CAP) was evaluated on Overall response rate (complete response and partial response). Combination chemotherapy with cis-platin, doxorubicin, and cyclophosphamide (CAP) achieved a 63% overall response rate in patients with metastatic breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: